Mirvetuximab Soravtansine-gynx
Am J Health Syst Pharm
.
2023 Mar 21;80(7):395-397.
doi: 10.1093/ajhp/zxad001.
PMID:
36807473
DOI:
10.1093/ajhp/zxad001
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized / adverse effects
Humans
Immunoconjugates*
Maytansine* / adverse effects
Substances
mirvetuximab soravtansine
Maytansine
Immunoconjugates
Antibodies, Monoclonal, Humanized